Scroll to top

Scroll to top

News Releases

News Releases

Month Year

Month Year

Investor Alerts

Jun 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
Apr 23, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing
Apr 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
Apr 17, 2020

Immunic, Inc. Announces Changes to Executive Team
Mar 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
Feb 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February

Show per page